📇 Rhumatologue · REIMS CEDEX · (51) · Salarié
Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
3 raisons identifiées
Auteur de référence en rhumatologie
38 articles scientifiques publiés — un praticien à la pointe de la recherche
Expérience confirmée
18 ans d'exercice en rhumatologie — recul clinique solide
Délais de RDV courts dans la région
134.8 rhumatos / 100 000 hab. — département bien doté
18ans d'exercice (thèse 2008)
✨ Génération du profil synthétique IA en cours…
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
Source : catalogue national des thèses theses.fr (ABES). Ne couvre que les doctorats / HDR — les thèses d'exercice (DES) sont archivées dans les SCD universitaires.
Indicateurs publics agrégés sur 250 M+ d'œuvres scientifiques (OpenAlex, PubMed). Traduits ici en langage patient.
Influence scientifique
22
22 articles ont été cités au moins 22fois par d'autres chercheurs — preuve que ses travaux sont repris par la communauté médicale.
h-index
Total citations reçues
2 764
Nombre de fois où d'autres équipes ont mentionné ses publications dans leurs propres travaux.
Publications totales
89
Articles, revues et chapitres référencés dans les bases académiques internationales.
Articles influents
38
Publications ayant marqué leur domaine — chacune citée au moins 10 fois par d'autres chercheurs.
i10-index
Thématiques principales
Affiliations FR : Institut Jean Godinot
Source : OpenAlex (CC0, OurResearch). Indicateurs académiques agrégés sur 250 M+ d'œuvres.
Articles déposés en accès libre sur l'archive ouverte des universités françaises (HAL) — gage d'activité de recherche en France.
Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study
2024ArticleLancet Oncology
Pattern and risk factors of isolated local relapse among women with hormone receptor-positive and HER2-negative breast cancer and lymph node involvement: 10-year follow-up analysis of the PACS 01 and PACS 04 trials
2023ArticleBreast Cancer Research and Treatment
Clinical outcome of patients with isolated central nervous system progression on first-line pertuzumab and trastuzumab treatment for HER2-positive metastatic breast cancer in a real-life cohort
2023ArticleBreast Cancer
Long-Term Results with Everolimus in Advanced Hormone Receptor Positive Breast Cancer in a Multicenter National Real-World Observational Study
2023ArticleCancers
Early Locoregional Breast Surgery and Survival in de novo Metastatic Breast Cancer in the Multicenter National ESME Cohort
2023ArticleAnnals of Surgery
Efficacy of taxanes rechallenge in first-line treatment of early metastatic relapse of patients with HER2-negative breast cancer previously treated with a (neo)adjuvant taxanes regimen: A multicentre retrospective observational study
2022ArticleThe Breast
Survival outcomes of metastatic breast cancer patients by germline BRCA1/2 status in a large multicenter real‐world database
2022ArticleInternational Journal of Cancer
Impact of lobular versus ductal histology on overall survival in metastatic breast cancer: a French retrospective multicentre cohort study
2022ArticleEuropean Journal of Cancer
Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).
INSTITUT GODINOT
1 R DU GENERAL KOENIG BP 171, 51056 REIMS CEDEX
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
The New England journal of medicine · 2019
Oncology · 2016
<b><i>Objectives:</i></b> Favorable phase I results justified this pilot phase II study to assess the efficacy of docetaxel/curcumin in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (CRPC). <b><i>Methods:</i></b> Thirty patients with progressing CRPC and a rising prostate-specific antigen (PSA) received docetaxel/prednisone in standard conditions for 6 cycles in combination with per os curcumin, 6,000 mg/day (day -4 to day +2 of docetaxel). The co-primary endpoint was the overall response rate determined by PSA and target assessments. An ancillary study assessed the seric values of chromogranin A (CgA) and neuron-specific enolase (NSE). <b><i>Results:</i></b> Twenty-six patients received the scheduled treatment, 2 progressed and 2 died before the end of treatment. A PSA response was observed in 59% of patients (14% of PSA normalization) and achieved within the first three cycles for 88% of responders. Partial response was reached for 40% of evaluable patients. The regimen was well tolerated, and no adverse event was attributed to curcumin. Twenty patients were 100% curcumin compliant. The PSA level and objective response rate were not correlated with the serum values of CgA and NSE. <b><i>Conclusion:</i></b> This study produced additional data on curcumin as a treatment for cancer, with a high response rate, good tolerability and patient acceptability, justifying the interest to conduct a randomized trial.
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
Breast cancer research and treatment · 2023 · Journal Article
Rassy E, Filleron T, Viansone A, Lacroix-Triki M, et al.
Breast cancer (Tokyo, Japan) · 2023 · Journal Article
Collet L, Eberst L, Ludovic G, Debled M, et al.
Annals of surgery · 2023 · Clinical Trial
Hotton J, Lusque A, Leufflen L, Campone M, et al.
Breast (Edinburgh, Scotland) · 2022 · Journal Article
Vasseur A, Carton M, Guiu S, Augereau P, et al.
Breast (Edinburgh, Scotland) · 2022 · Journal Article
Moinard-Butot F, Saint-Martin C, Pflumio C, Carton M, et al.
Therapeutic advances in medical oncology · 2022 · Journal Article
Carausu M, Carton M, Cabel L, Patsouris A, et al.
Breast cancer research and treatment · 2022 · Journal Article
Corbaux P, Lardy-Cleaud A, Alexandre M, Fontanilles M, et al.
Cancers · 2021 · Journal Article
Vano YA, Ladoire S, Elaidi R, Dermeche S, et al.
Clinical nuclear medicine · 2021 · Case Reports
Morland D, Godard F, Lalire P, Eymard JC, et al.
Therapeutic advances in medical oncology · 2021 · Journal Article
Bertho M, Fraisse J, Patsouris A, Cottu P, et al.
European journal of cancer (Oxford, England : 1990) · 2020 · Published Erratum
Delanoy N, Hardy-Bessard AC, Efstathiou E, Moulec SL, et al.
European journal of cancer (Oxford, England : 1990) · 2020 · Published Erratum
Delanoy N, Hardy-Bessard AC, Efstathiou E, Le Moulec S, et al.
Breast (Edinburgh, Scotland) · 2020 · Journal Article
Frank S, Carton M, Dubot C, Campone M, et al.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2020 · Journal Article
Pons-Tostivint E, Kirova Y, Lusque A, Campone M, et al.
European journal of cancer (Oxford, England : 1990) · 2020 · Journal Article
Delanoy N, Hardy-Bessard AC, Efstathiou E, Le Moulec S, et al.
The New England journal of medicine · 2019 · Comparative Study
de Wit R, de Bono J, Sternberg CN, Fizazi K, et al.
International journal of cancer · 2019 · Journal Article
Basse C, Italiano A, Penel N, Mir O, et al.
Breast cancer research and treatment · 2019 · Comparative Study
Cabel L, Carton M, Cheaib B, Pierga JY, et al.
BMC cancer · 2018 · Journal Article
Roché H, Eymard JC, Radji A, Prevost A, et al.
Medicine · 2018 · Journal Article
Dejust S, Morland D, Bruna-Muraille C, Eymard JC, et al.
European urology · 2018 · Clinical Trial, Phase III
Lavaud P, Gravis G, Foulon S, Joly F, et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024 · Clinical Trial, Phase III
Fizazi K, Le Teuff G, Fléchon A, Pagliaro L, et al.
European urology · 2024 · Randomized Controlled Trial
Colomba E, Jonas SF, Eymard JC, Delva R, et al.
European urology oncology · 2025 · Journal Article
Barthélémy P, Thibault C, Fléchon A, Gross-Goupil M, et al.
Clinical genitourinary cancer · 2025 · Journal Article
Staehler M, Basso U, Eymard JC, Barthelemy P, et al.
European journal of cancer (Oxford, England : 1990) · 2022 · Journal Article
Dalenc F, Lusque A, De La Motte Rouge T, Pistilli B, et al.
Annals of surgical oncology · 2019 · Comparative Study
Pons-Tostivint E, Kirova Y, Lusque A, Campone M, et al.
Oncology · 2016 · Clinical Trial, Phase II
Mahammedi H, Planchat E, Pouget M, Durando X, et al.
European urology · 2021 · Journal Article
Sternberg CN, Castellano D, de Bono J, Fizazi K, et al.
The Lancet. Oncology · 2020 · Clinical Trial, Phase IV
Fizazi K, Kramer G, Eymard JC, Sternberg CN, et al.
sj-jpg-1-tam-10.1177_17588359211070362 – Supplemental material for Real-world evidence of the management and prognosis of young women (⩽40 years) with de novo metastatic breast cancer
Supplemental material, sj-jpg-1-tam-10.1177_17588359211070362 for Real-world evidence of the management and prognosis of young women (⩽40 years) with de novo metastatic breast cancer by Amélie Mallet, Amélie Lusque, Chri
Clinicopathological characteristics and prognosis of breast cancer patients with isolated central nervous system metastases in the multicentre ESME database
Background:As a result of progress in diagnosis and treatment, there is a growing prevalence of metastatic breast cancer (MBC) with isolated CNS metastases. This study describes the largest-to-date real-life cohort of th
Real-world evidence of the management and prognosis of young women (⩽40 years) with <i>de novo</i> metastatic breast cancer
Background:Breast cancer (BC) in young women merits a specific approach given the associated fertility, genetic and psychosocial issues. <i>De novo</i> metastatic breast cancer (MBC) in young women is an even more seriou
sj-jpg-1-tam-10.1177_17588359211070362 – Supplemental material for Real-world evidence of the management and prognosis of young women (⩽40 years) with de novo metastatic breast cancer
Supplemental material, sj-jpg-1-tam-10.1177_17588359211070362 for Real-world evidence of the management and prognosis of young women (⩽40 years) with de novo metastatic breast cancer by Amélie Mallet, Amélie Lusque, Chri
Real-world evidence of the management and prognosis of young women (⩽40 years) with <i>de novo</i> metastatic breast cancer
Background:Breast cancer (BC) in young women merits a specific approach given the associated fertility, genetic and psychosocial issues. <i>De novo</i> metastatic breast cancer (MBC) in young women is an even more seriou
Clinicopathological characteristics and prognosis of breast cancer patients with isolated central nervous system metastases in the multicentre ESME database
Background:As a result of progress in diagnosis and treatment, there is a growing prevalence of metastatic breast cancer (MBC) with isolated CNS metastases. This study describes the largest-to-date real-life cohort of th
Source : DataCite — DOIs pour datasets, logiciels, protocoles, registres patient. Hors articles (déjà couverts).
Clinical genitourinary cancer · 2021 · Clinical Trial, Phase III
Culine S, Harter V, Gravis G, Fléchon A, et al.
Cancer medicine · 2021 · Clinical Trial, Phase II
Passildas-Jahanmohan J, Eymard JC, Pouget M, Kwiatkowski F, et al.
The Lancet. Oncology · 2020 · Clinical Trial, Phase IV
Fizazi K, Kramer G, Eymard JC, Sternberg CN, et al.
European journal of cancer (Oxford, England : 1990) · 2018 · Clinical Trial, Phase III
Campone M, Lacroix-Triki M, Roca L, Spielmann M, et al.
Oncology · 2016 · Clinical Trial, Phase II
Mahammedi H, Planchat E, Pouget M, Durando X, et al.
The oncologist · 2015 · Clinical Trial, Phase II
Wang-Lopez Q, Mouret-Reynier MA, Savoye AM, Abrial C, et al.
International journal of cancer · 2023 · Multicenter Study
Mailliez A, D'Hondt V, Lusque A, Caron O, et al.
Cancers · 2023 · Journal Article
François-Martin H, Lardy-Cléaud A, Pistilli B, Levy C, et al.
Therapeutic advances in medical oncology · 2022 · Journal Article
Mallet A, Lusque A, Levy C, Pistilli B, et al.
Anticancer research · 2020 · Journal Article
Heudel P, Delaloge S, Parent D, Madranges N, et al.